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 Wagner syndrome (OMIM 143200) is a rare vitreoretinal
degeneration inherited as an autosomal dominant trait. This
potentially blinding disease was first described in 1938 in a
large Swiss pedigree and has been identified subsequently in
several other families [1-5]. Penetrance in Wagner syndrome
is complete, and the disease manifests in childhood or adoles-
cence with a progressive course. Affected individuals usually
present an “empty” vitreous cavity with fibrillary condensa-
tion or avascular strands and veils. Additional features include
chorioretinal atrophy with loss of the retinal pigment epithe-
lium, lattice degeneration of the retina, complicated cataracts,
mild myopia and peripheral traction retinal detachment [6].
Rod and cone electroretinography (ERG) shows reduced b-
wave amplitude and correlates with severe chorioretinal pa-
thology [6]. These additional findings are extremely variable
and are age-dependent (Table 1). The pathogenic processes
leading to the complex eye phenotype of Wagner syndrome
are poorly understood. Most likely, however, liquefaction of
the vitreous initiates a degenerative cascade. Whether the ad-
ditional features evolve secondary to the degeneration of the
vitreous or represent independent features still remains to be
determined.
The chromosomal location of this disease (WAG1) had
initially been mapped in the original Wagner family to a 35-
cM region on chromosome 5q13-14 [7]. This region was later
reduced to 2 cM between markers D5S626 and CRTL1 [3,7].
Within this region several known genes can be found. One of
them is CSPG2, which encodes within 15 exons the large (3396
amino acids) chondroitin sulfate proteoglycan, versican [8,9].
Differential splicing of the two largest exons, 7 and 8, yields
four isoforms, which accumulate in a tissue-specific manner
[10,11]. Variant V0 contains both exons and can bind 17 to 23
glycosaminoglycan (GAG) chains, V1 lacks exon 7 and can
bind 12 to 15 GAGs, V2 lacks exon 8 and binds only 5 to 8
GAGs and V3 lacks both exons and hence has no GAG at-
tachment sites. Versican participates as a structural compo-
nent of the human vitreous. Both the chromosomal location
and its function make it a likely candidate for a pathogenic
factor causing the Wagner syndrome.
Perveen and colleagues analyzed 18 families with Wagner
syndrome. They found a single nucleotide exchange causing
an amino acid exchange within exon 7 of CSPG2 in only one
of the families and therefore did not consider versican the
pathogenic cause [3]. Recently, Miyamoto et al. [2] identified
a sequence alteration in intron 7 of CSPG2 leading to aberrant
RNA splicing, which co-segregated with Wagner syndrome
in a Japanese family.
Here we report on sequence analyses in the original
Wagner family of two candidate genes, CSPG2 and EDIL3,
which locate to the 2 cM region identified by Perveen et al.
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[3] and provide data that implicate a role of versican in the
development of Wagner syndrome.
METHODS
Patients:  All patients studied belong to the single large pedi-
gree originally described by Wagner in 1938 (updated pedi-
gree shown in Figure 1). Forty-six family members and 11
spouses were genetically analyzed. All family members had
received a complete clinical eye examination, which resulted
in unequivocal determination of the disease status. The clini-
cal follow-up of this cohort has been described in a previous
publication [6].
Mutation screening by DNA sequencing:  Between 50 and
100 ng of genomic DNA from the index patient IV/49 (Figure
1) was amplified by polymerase chain reaction (PCR) and
subjected to DNA sequence analysis using the ABI Prism 3100
or 377 system (Applied Biosystems, Rotkreuz, Switzerland).
Primers, spanning the 10 exons and flanking introns of EDIL3
(GenBank accession number NM_005711) and the 15 exons
and flanking introns of CSPG2 (GenBank accession number
NM_004385) were designed using Primer3 software. Primer
sequences and PCR conditions are available upon request. The
large exons 7 and 8 of CSPG2 were amplified in 5 and 12
overlapping fragments, respectively. All other exons could be
analyzed from a single PCR reaction. PCR fragments were
electrophoretically separated in 1 or 2% agarose, either ex-
cised and purified with a QIAquick Gel Extraction Kit (Qiagen;
Hombrechtikon, Switzerland) or cleaned with the EXOSAP
enzyme treatment (USB, Cleveland, OH) followed by sequenc-
ing. For most sequence alterations found in the index patient,
the corresponding sequence of the affected father and the un-
affected mother was also determined. Sequence of the splice
donor in intron 8 was determined from 47 family members.
Reverse transcriptase polymerase chain reaction experi-
ments:  RNA was extracted from venous blood of the index
patient IV/49 (Figure 1) using the Pre-Analytix System
(Qiagen), and its integrity and concentration was determined
with the Agilent system (Agilent, Basel, Switzerland). cDNA
was synthesized from 1 µg total RNA using the Superscript
III kit (Invitrogen, Basel, Switzerland) and 1 µl was subjected
to reverse transcriptase polymerase chain reaction (RT-PCR;
Table 1, Figure 2). Amplification with HotStar polymerase in
the presence of 2 mM MgCl2 (Qiagen) occurred in 35 cycles
of 1 min incubations each at 95 °C, 59 °C, and 72 °C in a
reaction volume of 25 µl. Reverse transcription and PCR re-
actions were obtained from two separate blood samples of the
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TABLE 1. CLINICAL FEATURES IN WAGNER SYNDROME
                                                      Observation in              Observations in
 Features            Ocular symptoms                 younger patients             older patients
----------   -------------------------------   -----------------------------   ---------------------
Hallmark     Empty vitreous with fibrillary    Frequent                        Not observed anymore
             condensations
             Avascular strands and veils       Frequent                        Almost always
Additional   Chorioretinal atrophy             Frequent                        Always present
             Rhegmatogenous retinal            Rare                            Not observed
             detachment
             Peripheral tractional retinal     Rare                            Common
             detachment
             Cataracts                         Frequent                        Does not apply
             Visual acuity                     Normal to subnormal             Severely affected
             Refractive error                  Frequent mild to moderate       Does not apply
                                               myopia
             Visual field                      Minor defects                   Marked field loss
             Abnormal pattern of the central   Rare                            Frequent
             retinal vessels
             Optic atrophy                     Not observed                    Frequent if advanced
                                                                               chorioretinal atrophy
             Electroretinography (ERG) dark    Frequently pathologic rod       Progressively
             adaptation                        threshold frequently elevated   pathologic
Patients of the original Wagner syndrome family were assigned to the older or younger group based on the age of approximately 30 years. This
age limit should be considered of gliding nature. The division into hallmark and additional features reflects our hypothesis that hallmark
features represent the primary defect while additional features may be of secondary, consequential nature. More detailed information about the
clinical observations can be found in the literature [4,6].
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index patient. The following primers were used: RTexon7f (5'-
CTC CTG CTA CAC AGC CAA CA-3'), RTexon8f (5'-AGG
TTG CAA CAC CAC CAT TT-3'), RT exon9r (5'-TCA CAC
TGG TCT CCG CTG TA-3'), and RTexon10r (5'-GCT CAC
AAA GTG CAC CAA CA-3'). Products were electrophoreti-
cally separated on 1% agarose or 3% Nusieve agarose (Agar-
ose 3:1, Eurobio, Brunschwig, Basel, Switzerland). DNA se-
quence was determined using the ABI 3100 sequencer as pre-
viously described. Potential splicing events were investigated
using the NNSPLICE software (Berkeley Drosophila Genome
Project, Berkeley, CA) [12].
RESULTS
DNA sequence analysis:  The search for disease-causing genes
led us to two potential candidates located in the region of 5q13-
14, to which the Wagner syndrome had been mapped. One of
them was EDIL3 (epidermal growth factor-like repeats and
discoidin I-like domains 3), an extracellular matrix protein.
The coding region of EDIL3 did not carry any mutation (data
not shown).
The other candidate gene was CSPG2. DNA sequence of
the index patient revealed 16 changes: ten of them in exons,
one in the promoter region, and four in introns. Most of them
are known single nucleotide polymorphisms (SNPs), except
the promoter and three intron changes (Table 2). Most of the
regions that showed known SNPs or novel changes in the in-
dex patient were also analyzed in the affected father and the
unaffected mother but did not segregate with the phenotype
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Figure 1. Pedigree of original Swiss family with dominantly inherited Wagner syndrome.  Filled symbols represent affected individuals.
Family members of generations III, IV, and V, who have been tested for the splice site mutation, are numbered. An arrow points to the index
patient. Clinical information on the eye phenotype of generation I is not available.
Figure 2. CSPG2 transcript analysis.
Schematic diagram (A) and gel electro-
phoresis (B) show the accumulation of
normal and aberrant splice products of
CSPG2 in control and patient venous
blood RNA as determined by RT-PCR
analysis. A: The size of exon (E) 7
through 10 and intron (IVS) 7 through 9
is given in base pairs (bp). IVS7 and
primers 7f, 8f, 9r, and 10r are not drawn
to scale. Primer arrows point to 3' direc-
tion. Asterisk (*) symbolizes the
c.9265+1G>A splice site mutation. To the
left of the diagrammed splice products is
indicated the sample in which the respec-
tive fragment was found. B: Ethidium
bromide stained agarose gel shows mi-
gration of the 1 kb molecular weight
marker (M) and RT-PCR products from
control (Co) and patient (P) RNA
samples. Expected fragment sizes are
noted below each primer combination.
Water templates (W) did not show any
amplification products.
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(Table 2). Of the novel changes only the G to A substitution in
intron 8 segregated with the disease status within this nuclear
family. Consequently, this mutation was tested in 47 mem-
bers of the entire Wagner family, and it segregated with the
phenotype in 21 affected and 26 unaffected individuals (Fig-
ure 1). It destroys the highly conserved splice donor sequence
of intron 8 of one allele (Figure 3). In 104 normal alleles, this
G residue was not mutated.
Transcript analysis:  Four different isoforms of versican
are regulated in a tissue-specific pattern [8-10]. In RT-PCR
experiments with RNA from venous blood from a normal con-
trol person, no fragments were amplified using primer pairs
7f/9r or 7f/10r (Figure 2). This is expected if exon 8 (5262 bp)
is present in the transcript and PCR conditions were not opti-
mized for amplification of larger products. In contrast, RNA
from the index patient IV/49 (Figure 1) with the splice donor
site mutation IVS8+1G>A resulted in amplification of a 259
bp fragment with primer pair 7f/9r and a 375 bp fragment
with primer pair 7f/10r (Figure 2). DNA sequence was deter-
mined from both RT-PCR fragments and showed splicing of
exon 7 to exon 9. To investigate the splice events of intron 8
further, primers 8f/9r and 8f/10r were used. In the control
sample, one fragment of 214 bp and one of 330 bp in size was
amplified with primer pairs 8f/9r and 8f/10r, respectively. DNA
sequence of these fragments revealed splicing of exon 8 to
exon 9. In RNA samples from the index patient, the same size
RT-PCR fragments yielding the same sequence were obtained,
as expected due to the heterozygous mutation. In addition,
both primer pairs resulted in the amplification of a slightly
shorter fragment, which was only visible as a faint band after
electrophoresis in 3% agarose Nusieve gel (data not shown).
We determined the sequence of this fragment, which was re-
vealed to lack the last 21 base pairs of exon 8 (sequence not
shown), and which may lead to an in frame deletion of seven
amino acid residues.
DISCUSSION
 We have shown that a heterozygous mutation of the highly
conserved splice donor site in intron 8 of the CSPG2 gene
segregates with the dominant disease status in the original
Wagner family. Moreover, we confirmed that the mutation
produces aberrantly spliced CSPG2 transcripts.
Argument for pathogenic mutation:  Genetically, Wagner
syndrome had been mapped to the 5q13-14 chromosomal in-
terval. Within this region, eight known and three hypothetical
genes are located (Genome Browser, version 107). Two of the
known genes, EDIL3 and CSPG2, encode proteins with func-
tions in the extracellular matrix and seemed likely candidates
to affect the vitreous gel. Neither we nor others [2] found a
mutation in EDIL3 and therefore excluded this gene from be-
ing involved in the development of Wagner syndrome. In con-
trast, the destruction of the highly conserved splice donor site
of intron 8 of the CSPG2 gene perfectly co-segregates with
the disease phenotype and was not found in normal alleles.
Recently, a mutation in CSPG2, also causing a splicing de-
fect, was reported to segregate in a Japanese family with
Wagner syndrome [2]. Together with an earlier finding of a
nucleotide transition mutation in exon 7 of CSPG2 in a differ-
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TABLE 2. CSPG2 SEQUENCE ALTERATIONS
                                               Sequence results
                                         -----------------------------
                              Protein            Affected   Unaffected      SNP
Location    SNP/DNA change     change    Index    father      mother     reference
---------   ---------------   --------   -----   --------   ----------   ----------
Promoter    -648A>G                       G                              novel
Exon 3      c.587C>T          p.T116T     T                              rs12332199
Exon 5      c.884G>A          p.V215V     A      G/A         G/A         rs4470745
Exon 8      c.1601G>A         p.Q454Q     A      G/A         A           rs2548541
Exon 8      c.1825A>G         p.K529R     G      A/G         A/G         rs309559
Exon 8      c.2755G>A         p.R839H     A      A           A           rs188703
Exon 8      c.3086T>C         p.G949G     C      T/C                     rs309557
Exon 8      c.4001A>G         p.R1254R    G      A/G         A/G         rs160279
Exon 8      c.4180T>A         p.F1314Y    A      T/A         T/A         rs160278
Exon 8      c.6087G>T         p.D1950Y    T      G/T         G/T         rs160277
Exon 14     c.7160C>T         p.V2307V    T      T           T           rs308365
Intron 8    c.9265+1G>A                   G/A    G/A         G           novel
Intron 9    c.9380-181G>A                 A                              rs7728751
Intron 9    c.9380-75insACT               ACT    ---/ACT     ---/ACT     novel
Intron 10   c.9513-63T>A                  A                              rs6873404
Intron 11   c.9653-149A>G                 G      A/G         A/G         novel
Sequence alterations in CSPG2 of index patient IV/49, affected father III/22 and unaffected mother II/23 (Figure 1). Nucleotide position based
on cDNA and protein changes are listed. The disease-causing mutation in intron 8 is printed in bold. Substitutions (>) and insertions (ins) are
indicated. In the index patient, all alterations except the disease-causing change in intron 8 appear homozygous. Known single nucleotide
polymorphisms (SNPs) are listed by their identification number (dbSNP). Reference sequence for CSPG2 is from GenBank accession number
NM_004385.
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ent Wagner family [3], these data provide strong evidence that
mutations in the CSPG2 gene are the underlying genetic de-
fect in Wagner syndrome.
Hypothesis of the disease mechanism:  CSPG2 encodes a
large extracellular chondroitin sulfate proteoglycan, versican,
which is 3396 amino acids in length with about a 370 kDa
mass [8,9]. The protein is secreted and found in many extra-
cellular matrices, including the vitreous gel. It forms large
aggregates via bound hyaluronan at the N-terminus and GAG
at specific attachment sites (GAG α and β), which reside in
the middle section of the protein, and it most likely partici-
pates in the establishment and maintenance of supramolecu-
lar structures. The middle section of the protein is encoded by
two large exons, 7 and 8, whose presence or absence deter-
mines the identity of four different variants of versican. Vari-
ant V0 contains both exons, V1 contains exon 8, V2 contains
exon 7, and V3 lacks both exons. Accordingly, the number of
GAG side chains varies (V0 has 17-23, V1 has 12-15, V2 has
5-8, and V3 has none). The four splice variants accumulate at
rather strikingly different levels in a tissue-dependent man-
ner. Within the eye, transcripts of all four splice variants have
been found in the retina, the trabecular meshwork and the cili-
ary muscle [2,10,13]. The retina expresses mainly the V3 tran-
script [2], while in the trabecular meshwork, and the ciliary
muscle, the V1 mRNA prevails [13]. It is not clear which of
these tissues contributes versican to the mostly acellular vit-
reous gel [14]. In our Swiss Wagner family, destruction of the
splice donor site of intron 8 leads to ectopic expression of
versican V2 mRNA in leukocytes. It seems possible that
upregulation of the V2 variant and haploinsufficiency of the
V0 and V1 variant may also occur in the tissues, which con-
tribute to vitreous development and maintenance.
The effect and the mechanism by which the second aber-
rant transcript, which contains almost all of exon 8 with the
exception of the last 21 base pairs, could have been generated
are not clear. Most likely the activation of a cryptic donor site
within exon 8 is involved although a search for such sites did
not reveal obvious sequence candidates within reasonable vi-
cinity. Translation of this aberrant transcript would result in a
protein lacking the last seven amino acids of exon 8. No known
function can be assigned to these skipped seven amino acids.
Whether this transcript participates in the pathogenicity of the
Wagner syndrome remains to be examined.
Defective splicing of CSPG2 transcripts is also discussed
as the pathogenic cause of Wagner syndrome in a Japanese
family [2], in which alteration of the splice acceptor site of
intron 7 was found to be mutated, leading to haploinsufficiency
of V0 and V1. This deficiency of V0/V1 and hence of
glygosaminoglycane attachment sites is common to both the
original Swiss and the Japanese Wagner families, supporting
the hypothesis that splicing defects of CSPG2 may lead to the
vitreoretinopathy.
As versicans interact through their C-terminal globular
domain with fibrillin-1 [15], they may be responsible for main-
taining the spatial separation of hyaluronan, the microfibrillar
structures and the collagen fibers. In this model, the GAG
containing middle portions are likely to play a crucial role in
keeping the fibrillar structures apart, preventing tangling and
aggregation of the collagen fibers. Relative overproduction of
variants V2 or V1 and deficiency of V0 in Wagner syndrome
would lead to altered core protein size, thereby affecting in-
teractions with other extracellular matrix components and con-
sequently disturbing the ultrastructural organization of the vit-
reous gel. This could cause accelerated liquefaction of vitre-
ous gel and finally manifesting in the “empty” vitreous ob-
served in Wagner patients.
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